Dr. Amaravadi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Civic Center Blvd
Fl 23
Philadelphia, PA 19104Phone+1 215-615-5858Fax+1 215-615-3349
Education & Training
- University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2003 - 2006
- Brigham and Women's HospitalResidency, Internal Medicine, 2000 - 2003
- Johns Hopkins University School of MedicineClass of 2000
- Columbia UniversityB.A., Biochemistry, Magna Cum Laude, 1996
Certifications & Licensure
- PA State Medical License 2003 - 2024
- MA State Medical License 2002 - 2004
Awards, Honors, & Recognition
- 2011 Most Cited Article in Clinical Cancer Research 2013
- Steinberg Scholar Abramson Cancer Center, 2012
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Join now to see all
Clinical Trials
- Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors Start of enrollment: 2008 Jun 01
- Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment Start of enrollment: 2008 Oct 01
- Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma Start of enrollment: 2009 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 1760 citationsRadiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancerChristina Twyman-Saint Victor, Andrew J. Rech, Amit Maity, Ramesh Rengan, Kristen E. Pauken
Nature. 2015-04-16 - 135 citationsPPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer.Vito W. Rebecca, Michael C. Nicastri, Colin Fennelly, Cynthia I. Chude, Julie S. Barber-Rotenberg
Cancer Discovery. 2019-02-01 - 333 citationsTargeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanomaXiao Hong Ma, Sheng Fu Piao, Souvik Dey, Quentin McAfee, Giorgos C. Karakousis
The Journal of Clinical Investigation. 2014-03-03
Journal Articles
- Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-Exposure SARS-CoV-2 Prophylaxis Among Health Care WorkersMatthew C Hyman, Ian Frank, Scott E Hensley, Saar Gill, Dan T Vogl, Ivan Maillard, Daria V Babushok, Alexander C Huang, Sunita D Nasta, Jennifer C Walsh, Michael C Mil..., JAMA Internal Medicine
- Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-cell PopulationsZeynep Eroglu, Iman Osman, Theodore S Nowicki, Antoni Ribas, Michael A Davies, Farbod Darvishian, Daniel Y Wang, Douglas B Johnson, Ravi K Amaravadi, Clinical Cancer Research
- Autophagy in malignant transformation and cancer progressionGalluzzi L, Pietrocola1 F, Bravo-San Pedro JM, Amaravadi RK, Cecconi F, Codogno P, Debnath J, Karantza V, Kumar S, Levine B, Maiuri MC, Martin S, Penninger J, Piacen..., EMBO J, 1/1/2015
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Mouse models address key concerns about autophagy inhibition for cancer therapy.Amaravadi RK, Debnath J, Cancer Discovery, 1/1/2014
- PUMA: a puzzle piece in chloroquine's antimelanoma activity.Amaravadi RK, Journal of Investigative Dermatology, 1/1/2013
- Efficacy, Safety and Pharmacokinetics of a new formulation of the BRAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib from Part D of a Phase ...R. Amaravadi, R. Kudchadkar, R. Gonzalez, D. Lawrence, J. Sosman, J.R. Infante, A. Daud, R. F. Kefford, J. Cebon, W. Sharfman, L. Schuchter, P. Boasberg, K. Lewis, K...., J Clin Oncology; American Society of Clinical Oncology annual meeting, 1/1/2013
- Join now to see all
Lectures
- Targeting Autophagy in CancerUniversity of Arizona Cancer Center, Tucson, AZ - 1/1/2015
- Advances in Melanoma1/1/2015
- Targeted therapies for melanoma.1/1/2015
- Join now to see all
Authored Content
- SMR 2021: Elevating the Standards for Virtual MeetingsNovember 2021
Press Mentions
- Penn Medicine, Wistar Institute Get $11.7M NCI Grant to Develop Potential Melanoma TreatmentsSeptember 24th, 2021
- Penn Medicine and Wistar Institute Receive $11.7 Million Grant to Treat MelanomaSeptember 24th, 2021
- Penn Medicine and Wistar Secure $11.7 Million SPORE Grant for Three Melanoma Research ProjectsSeptember 22nd, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: